Oral Antibiotics for Spontaneous Bacterial Peritonitis
For uncomplicated community-acquired SBP, oral ofloxacin 400 mg twice daily is as effective as intravenous cefotaxime and represents the primary oral option, while oral amoxicillin-clavulanic acid (after initial IV dosing) and oral ciprofloxacin (as step-down therapy) are alternative oral strategies. 1
Primary Oral Antibiotic Options
Ofloxacin (First-Line Oral Option)
- Dosing: 400 mg orally twice daily
- Efficacy: Demonstrated 84% infection resolution rate, equivalent to IV cefotaxime (85%) 1
- Patient Selection Criteria (all must be met):
Amoxicillin-Clavulanic Acid (Sequential IV-to-Oral)
- Dosing: Start with 1 g/0.2 g IV every 8 hours, then switch to 500 mg/125 mg orally every 8 hours
- Efficacy: 87.5% resolution rate, comparable to cefotaxime 1, 3
- Advantage: Significantly lower cost than IV cephalosporins
- Caution: Single small study; concern for drug-induced liver injury 4
Ciprofloxacin (Step-Down Therapy)
- Dosing: 200 mg IV twice daily for 2 days, followed by 500 mg orally twice daily for 5 days
- Efficacy: 76% resolution rate, similar survival to cefotaxime 1, 3
- Cost-effectiveness: More economical than continuous IV cefotaxime when used as switch therapy 1
Critical Contraindications to Quinolones
Do NOT use quinolones (ofloxacin/ciprofloxacin) in these scenarios 1:
- Patients already on quinolone prophylaxis for SBP
- Nosocomial or healthcare-associated SBP
- Areas with high quinolone resistance (>30% E. coli resistance)
- Recent quinolone exposure
- Sepsis or septic shock at presentation
The Korean guidelines specifically note quinolone resistance in E. coli has reached 31.7% in some centers, making empiric quinolone use increasingly problematic 3.
Treatment Duration and Monitoring
- Standard duration: 5-7 days total 1, 5
- Response assessment: Repeat paracentesis at 48 hours
- Ascitic fluid PMN should decrease to <25% of baseline 1
- Failure to respond warrants antibiotic change and evaluation for secondary peritonitis
- Treatment failure indicators: Worsening symptoms or PMN count not decreasing appropriately 1
Important Caveats
Emerging Resistance Patterns
The 2018 KASL guidelines and 2018 EASL guidelines emphasize that multi-drug resistant organisms (MDROs) have fundamentally changed SBP management 3, 4. Gram-positive organisms (Staphylococcus, Enterococcus) now represent a significant proportion of cases, and fluoroquinolone resistance is increasing globally 6.
When Oral Therapy is NOT Appropriate
Patients requiring broad-spectrum IV antibiotics from the start include those with 5, 4:
- Healthcare-associated or nosocomial SBP
- Recent broad-spectrum antibiotic exposure
- Sepsis or septic shock
- Any complicated SBP features (shock, severe encephalopathy, renal failure)
Albumin Administration
Regardless of antibiotic route, all SBP patients should receive IV albumin (1.5 g/kg at diagnosis, 1 g/kg on day 3), particularly those with creatinine ≥1 mg/dL or bilirubin ≥4 mg/dL, as this reduces mortality from 29% to 10% 1, 5.
Practical Algorithm
For uncomplicated community-acquired SBP:
- Confirm patient meets criteria (no shock, encephalopathy ≤grade I, creatinine <3 mg/dL, no GI bleeding, no prior quinolone use)
- Start oral ofloxacin 400 mg twice daily
- Administer IV albumin per protocol
- Repeat paracentesis at 48 hours to confirm response
- Complete 5-7 days of therapy
For all other SBP cases:
- Start IV third-generation cephalosporin (cefotaxime or ceftriaxone)
- Consider step-down to oral ciprofloxacin after clinical improvement if cultures show susceptibility
- Broaden coverage if nosocomial or MDRO risk factors present
The evidence strongly supports that oral therapy can be highly effective in carefully selected patients with uncomplicated SBP, but the changing resistance landscape demands careful patient selection and close monitoring 1, 3, 5.